L’IMPIEGO CLINICO DI UNA NUOVA CLASSE DI FARMACI ANTICOAGULANTI: GLI INIBITORI DIRETTI DELLA TROMBINA

Salvatore Novo, Salvatore Novo, Danilo Puccio

    Risultato della ricerca: Article

    1 Citazione (Scopus)

    Abstract

    The coagulation cascade, and particularly thrombin, plays a very important role in arterial and venousthrombosis. Thereby, it is clear that thrombin inactivation is an optimal strategy for thromboticdisease prevention and treatment. The direct thrombin inhibitors are a new class of anticoagulantdrugs directly binding thrombin and blocking its interaction with fibrinogen. The group of directthrombin inhibitors includes recombinant hirudin (lepirudin and desirudin), bivalirudin, melagatranand its oral precursor, ximelagatran, argotraban and dabigatran. These drugs have several advantagescompared to other anticoagulant drugs, and the particular pharmacokinetic properties of someof them could be very important for future management of thromboembolic prophylaxis.The efficacy and safety of these new drugs are evaluated in several clinical trials; however todayonly few clinical indications are available for the majority of them.
    Lingua originaleItalian
    pagine (da-a)739-746
    Numero di pagine8
    RivistaDefault journal
    Volume7
    Stato di pubblicazionePublished - 2006

    All Science Journal Classification (ASJC) codes

    • Cardiology and Cardiovascular Medicine

    Cita questo

    L’IMPIEGO CLINICO DI UNA NUOVA CLASSE DI FARMACI ANTICOAGULANTI: GLI INIBITORI DIRETTI DELLA TROMBINA. / Novo, Salvatore; Novo, Salvatore; Puccio, Danilo.

    In: Default journal, Vol. 7, 2006, pag. 739-746.

    Risultato della ricerca: Article

    @article{8497f36815d0461ba479bced8115de52,
    title = "L’IMPIEGO CLINICO DI UNA NUOVA CLASSE DI FARMACI ANTICOAGULANTI: GLI INIBITORI DIRETTI DELLA TROMBINA",
    abstract = "The coagulation cascade, and particularly thrombin, plays a very important role in arterial and venousthrombosis. Thereby, it is clear that thrombin inactivation is an optimal strategy for thromboticdisease prevention and treatment. The direct thrombin inhibitors are a new class of anticoagulantdrugs directly binding thrombin and blocking its interaction with fibrinogen. The group of directthrombin inhibitors includes recombinant hirudin (lepirudin and desirudin), bivalirudin, melagatranand its oral precursor, ximelagatran, argotraban and dabigatran. These drugs have several advantagescompared to other anticoagulant drugs, and the particular pharmacokinetic properties of someof them could be very important for future management of thromboembolic prophylaxis.The efficacy and safety of these new drugs are evaluated in several clinical trials; however todayonly few clinical indications are available for the majority of them.",
    author = "Salvatore Novo and Salvatore Novo and Danilo Puccio",
    year = "2006",
    language = "Italian",
    volume = "7",
    pages = "739--746",
    journal = "Default journal",

    }

    TY - JOUR

    T1 - L’IMPIEGO CLINICO DI UNA NUOVA CLASSE DI FARMACI ANTICOAGULANTI: GLI INIBITORI DIRETTI DELLA TROMBINA

    AU - Novo, Salvatore

    AU - Novo, Salvatore

    AU - Puccio, Danilo

    PY - 2006

    Y1 - 2006

    N2 - The coagulation cascade, and particularly thrombin, plays a very important role in arterial and venousthrombosis. Thereby, it is clear that thrombin inactivation is an optimal strategy for thromboticdisease prevention and treatment. The direct thrombin inhibitors are a new class of anticoagulantdrugs directly binding thrombin and blocking its interaction with fibrinogen. The group of directthrombin inhibitors includes recombinant hirudin (lepirudin and desirudin), bivalirudin, melagatranand its oral precursor, ximelagatran, argotraban and dabigatran. These drugs have several advantagescompared to other anticoagulant drugs, and the particular pharmacokinetic properties of someof them could be very important for future management of thromboembolic prophylaxis.The efficacy and safety of these new drugs are evaluated in several clinical trials; however todayonly few clinical indications are available for the majority of them.

    AB - The coagulation cascade, and particularly thrombin, plays a very important role in arterial and venousthrombosis. Thereby, it is clear that thrombin inactivation is an optimal strategy for thromboticdisease prevention and treatment. The direct thrombin inhibitors are a new class of anticoagulantdrugs directly binding thrombin and blocking its interaction with fibrinogen. The group of directthrombin inhibitors includes recombinant hirudin (lepirudin and desirudin), bivalirudin, melagatranand its oral precursor, ximelagatran, argotraban and dabigatran. These drugs have several advantagescompared to other anticoagulant drugs, and the particular pharmacokinetic properties of someof them could be very important for future management of thromboembolic prophylaxis.The efficacy and safety of these new drugs are evaluated in several clinical trials; however todayonly few clinical indications are available for the majority of them.

    UR - http://hdl.handle.net/10447/17839

    M3 - Article

    VL - 7

    SP - 739

    EP - 746

    JO - Default journal

    JF - Default journal

    ER -